Company Overview

PURE Bioscience, Inc. is a U.S.-based life sciences company focused on the development and commercialization of antimicrobial products primarily for food safety, agriculture, and industrial applications. The company operates within the food safety, agricultural inputs, and industrial sanitation industries, with a core emphasis on reducing microbial contamination using non-antibiotic, silver-based chemistry. Its primary revenue drivers are products formulated with its proprietary antimicrobial technology, marketed to food processors, growers, and industrial customers seeking pathogen control solutions that align with regulatory and sustainability requirements.

The company’s core technology is silver dihydrogen citrate (SDC), a patented antimicrobial compound positioned as an alternative to traditional chemical sanitizers and antibiotics. PURE Bioscience emphasizes its technology’s efficacy at low concentrations and its compatibility with food-contact and agricultural environments as a key strategic advantage. Founded in the mid-1990s, the company initially focused on wound care and medical applications before pivoting toward food safety and agriculture, reflecting shifts in regulatory pathways, capital availability, and market demand over time.

Business Operations

PURE Bioscience conducts operations primarily through the development, regulatory approval, and commercialization of antimicrobial products based on its SDC technology. The company generates revenue through product sales, licensing arrangements, and distribution partnerships, with its offerings used for microbial control in food processing, produce washing, animal health, and agricultural water treatment applications. Operations are largely centralized, with manufacturing outsourced to third-party partners under controlled specifications.

The company’s business is primarily domestic, with U.S. customers accounting for the majority of commercial activity, though products are marketed for international use subject to local regulatory approvals. PURE Bioscience controls a portfolio of patents and intellectual property related to silver-based antimicrobials and maintains relationships with distributors and strategic partners rather than operating extensive physical infrastructure. Information on material joint ventures or wholly owned operating subsidiaries beyond the core corporate entity is limited; data inconclusive based on available public sources.

Strategic Position & Investments

Strategically, PURE Bioscience is focused on expanding adoption of its SDC-based products in food safety and agriculture by securing regulatory clearances, broadening distribution, and demonstrating efficacy versus conventional antimicrobials. Growth initiatives have historically centered on penetrating high-risk pathogen control markets, including fresh produce and protein processing, where regulatory scrutiny and contamination risk are elevated.

The company has pursued selective investments in product development and intellectual property rather than large-scale acquisitions. Its strategic positioning emphasizes participation in emerging demand for non-antibiotic antimicrobial solutions amid increasing regulatory and consumer pressure to reduce chemical residues and antimicrobial resistance. Public disclosures indicate limited acquisition activity; no material acquired company names can be independently verified from available filings, and information on minority investments or portfolio companies is inconclusive.

Geographic Footprint

PURE Bioscience is headquartered in the United States, with its primary corporate, regulatory, and commercial activities centered domestically. The company’s market presence is strongest in North America, where it engages with food processors, agricultural producers, and industrial users operating under U.S. regulatory frameworks.

Internationally, PURE Bioscience has sought to extend its reach through distributors and regulatory submissions in select foreign markets, including parts of Latin America, Asia-Pacific, and Europe, where permitted. However, the company does not report a significant physical operating footprint outside the United States, and international influence is primarily commercial and regulatory rather than operational. Detailed country-level revenue breakdowns are not consistently disclosed; data inconclusive based on available public sources.

Leadership & Governance

PURE Bioscience was founded by Hank Lambert, who has played a central role in shaping the company’s strategic direction and technology focus. Leadership has emphasized disciplined capital management, regulatory validation, and targeted commercialization rather than rapid scale, reflecting the company’s development-stage profile and niche market strategy.

Key executives publicly associated with the company include:

• Hank Lambert – Chief Executive Officer and Chairman of the Board

Publicly available filings and disclosures provide limited, and at times inconsistent, detail regarding additional senior executives and management roles beyond the CEO and board level. As a result, comprehensive verification of other current executive positions is not possible based on available public sources.